Sanofi’s Brivekimig Shows Promising Results in Hidradenitis Suppurativa

Sanofi’s brivekimig achieved the primary endpoint in a Phase IIa trial (HS-OBTAIN, NCT05849922) for biologic-naïve patients with moderate-to-severe hidradenitis suppurativa (HS). Presented at EADV 2025, treatment led to a 67% response on HiSCR50 (≥50% reduction in abscess and inflammatory nodule count with no increase in abscess or draining fistulas), compared with 37% for placebo. Secondary endpoints, HiSCR75 and HiSCR90, showed response rates of 54% and 31% versus 22% and 9% for placebo. Draining tunnel counts decreased by 56% in the brivekimig group, while increasing 10.9% with placebo.

The subcutaneous monoclonal antibody was well tolerated; the most common adverse events were nasopharyngitis and headache. The study supports dual TNF and OX40L pathway inhibition as a potential strategy for HS. Brivekimig is also under investigation for glomerulonephritis, type 1 diabetes, ulcerative colitis, and Crohn’s disease.

The HS market is projected to grow from $1.84bn in 2024 to $7.83bn by 2034, driven by novel biologics.

22-09-2025